Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 139.52
Key Takeaways
Risk factor
Considerable default risk
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of INSM is 212 and suggests 53% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell